Participate in a Study

Currently, 9.2 million Americans have Alzheimer’s disease, the most common form of dementia. By 2050, that number is projected to rise to 58 million. Though so many are affected, challenges in finding volunteers hinders our efforts at developing a cure. As a research volunteer, you champion the effort to prevent, slow, and, one day, cure Alzheimer’s disease and related dementias

Participation in research is the only way we can hope to find cures for diseases such as Alzheimer's disease and promote normal healthy brain aging for all!

We have a variety of studies for individuals with and without memory loss.  To discuss how you can participate please call us at (859) 323-5550. Alternatively, you can give us some basic information by completing our online research interest form and we'll get back in touch with you soon. Click here to access the research interest form.

 

Featured Studies

UK ADC Brain Aging Research Study

The UK-Alzheimer’s Disease Center brain aging research program is our longest-running research study for individuals with and without memory problems. This is a unique opportunity to contribute to ongoing research in the areas of Alzheimer's disease and normal aging. Read Brain Aging Flyer Here.

The Alzheimer Prevention Trials Webstudy (APT)
The APT Webstudy –aptwebstudy.org- is an online memory and thinking research tool aimed at accelerating enrollment into Alzheimer’s clinical trials by identifying and tracking individuals who may be at higher risk for developing Alzheimer’s. Participation in the APT Webstudy involves taking online memory and thinking testing 4 times per year. You may be eligible to participate if you are age 50 or older and are interested in being part of future Alzheimer’s disease prevention trials. Click here to download the study flyer (pdf).

The AHEAD Study
The purpose of the AHEAD study (https://www.a3a45.org/) is to evaluate whether BAN-2401, a study drug, can help reduce the risk of developing AD dementia among individuals who are cognitively normal and have intermediate or elevated levels of amyloid. Participation in this research study will involve visits every two to four weeks over a four year period to receive the study drug via infusion. Participants will receive either the study drug or a placebo. You may be eligible to participate if you are ages 55-80, are in good general health, and are able to have an MRI scan. 

Clarity-AD

The purpose of the Clarity study is to evaluate whether BAN2401, a study drug, may slow or stop the progression of memory problems among individuals with mild cognitive impairment or mild Alzheimer’s disease. Participation in this research study will involve visits every two weeks over an 18-month period to receive the study drug via infusion. Participants will receive either the study drug or a placebo. An extension is currently planned for individuals who complete the study to have the chance to be guaranteed the drug for up to two years. You may be eligible to participate if you are ages 50-90, are in good general health, and are able to have an MRI scan. Click here to download the study flyer (pdf).



Ongoing Studies Closed for Enrollment

AWARE

The purpose of the AWARE study is to test whether a new drug called ABBV-8E12 is safe and if it can slow down Alzheimer’s disease when recognized very early.  Participation in this research study will involve 30 visits over the course of 27 months.  Participants will receive either a low, medium, or high dose of the medication or a placebo through an IV once a month.  You may be eligible to participate if you are ages 55-85 and have a diagnosis of mild cognitive impairment or mild Alzheimer’s disease, are in good general health, and are able to have an MRI scan. Click here to download the study flyer (pdf).


A4: Anti-Amyloid for Asymptomatic Alzheimer’s

The purpose of the A4 study is to evaluate the study treatment (solanezumab) for people with normal cognition who are at risk for developing Alzheimer’s disease on the basis of having biomarker evidence of amyloid.  This study will test the hypothesis that decreasing amyloid burden during the preclinical stages of Alzheimer’s disease will delay future cognitive decline.  Participants will receive treatment for 3 years with either the anti-amyloid infusion drug or the placebo. (www.a4study.org). You may be eligible to participate if: You are 65-85 years old, have normal cognition, and are able to have an MRI scan.  Click here to download the study flyer (pdf).


BAN-2401

The purpose of the BAN-2401 study is to examine whether an anti-amyloid medication may slow or stop the progression of Alzheimer’s disease in people with mild cognitive impairment and mild Alzheimer’s disease.  We hope to find out whether the study medication can reduce the amount of amyloid in the brain that might be causing the memory and thinking problems.  Participation in this research study lasts 2 years and involves bi-weekly infusions of the study drug or a placebo (www.nia.nih.gov/alzheimers/clinical-trials/ban2401-early-alzheimers-disease). You may be eligible to participate if: you are 50 years of age or older and have either mild cognitive impairment or mild Alzheimer’s disease. Click here to download the study flyer (pdf).

 

DELPHIA

The purpose of the Delphia study is to see if a new medication might improve cognitive function, including attention, memory, and language in patients who have Dementia with Lewy Bodies. Participation in this research study will involve 10 visits over 22 weeks. You may be eligible to participate if you are ages 50-85, have a diagnosis of Dementia with Lewy Bodies, are in good general health, and are able to have an MRI scan. Click here to download the study flyer (pdf).

 

EXERT

The purpose of the EXERT study is to examine the effects of two different kinds of exercise (stretching balance, range of motion versus moderate-to-high intensity aerobic exercise) on memory and thinking.  Participation in this study involves exercising 4 times a week at the High Street YMCA for 18 months (https://www.nia.nih.gov/alzheimers/clinical-trials/exercise-adults-mild-memory-problems-exert).  You may be eligible to participate if: You are 65-89 years old, have mild problems with memory and thinking, are able to have an MRI, and are not currently exercising. Click here to download the study flyer (pdf).

 

INCREASE

The purpose of the INCREASE study is to evaluate how your medication may impact memory and thinking.  Participating in this study will involve the use of a scopolamine patch to help us understand the effect of potentially inappropriate medications on your memory and thinking.  You may be eligible for this study if: you are 65 years of age or older and do not have dementia. Click here to download the study flyer (pdf).

 

T2 PROTECT

The purpose of the T2 Protect research study is to test the safety, effectiveness and tolerability of a new drug (BHV-4157). Participation in this research study will involve 9 visits over the course of 1 year. Participants will receive either the active medication or a placebo. You may be eligible to participate if you are ages 50-85, have a diagnosis Alzheimer’s disease, are in good general health, and are able to have an MRI scan. Click here to download the study flyer (pdf).

No